1. HBW Insight
  2. >>Beauty
  3. >>Policy & Regulation
  4. >>Legal

L’Oreal USA Faces First In Potential Wave Of Lawsuits Over Hair Straightener-Uterine Cancer Link

 
• By Ryan Nelson

In her complaint against L’Oreal and other marketers of hair-smoothing products, plaintiff Jenny Mitchell, who was diagnosed with uterine cancer in August 2018, cites an NIH study published in October as “the first epidemiologic evidence of association between use of straightening products and uterine cancer.” She claims the defendants engaged in negligent or fraudulent practices in their marketing and sale of hair-straightening products that they knew posed dangers to users.

Hair-straightening products from L’Oreal USA, Inc. and co-defendants contain phthalates and other endocrine-disrupting substances that consumers should have been warned about due to cancer risks, according to plaintiff Jenny Mitchell, who was diagnosed with uterine cancer in August 2018.

In a complaint filed on 21 October in Illinois federal court, Mitchell alleges that L’Oreal USA, Strength of Nature Global, LLC, Soft Sheen Caron Inc., Dabur USA, Inc., and Namaste...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal

Supreme Court 1935 Ruling Limiting Executive Authority On Appointments ‘Unravels’ Today – DoJ

 
• By Malcolm Spicer

In complaint and response to motion to dismiss, Rebecca Kelly Slaughter’s and Alvaro Bedoya’s attorneys elaborate on Supreme Court ‘s 1935 decision, Humphrey’s Executor v. US. Administration attorneys, though, contend the ruling isn’t relevant to the current FTC.

Estee Lauder Faces Securities Fraud Suit After District Court Denies Motion To Dismiss

 
• By Eileen Francis

A federal judge in the Southern District of New York denied Estee Lauder’s motion to dismiss a securities fraud lawsuit filed by shareholders who said the company concealed its reliance on a gray market retail revenue stream, which ultimately caused sales and the stock price to plunge.

Uncertainty Abounds With SEC Climate Reporting Rule Tied Up In Courts

 
• By Lauren Nardella

Despite questions surrounding the SEC rule, including disputes being litigated in the US Eighth Circuit, companies must prepare to meet the new climate disclosure requirements in addition to related mandates in California and abroad. Experts emphasize opportunities beyond compliance.

In Emergency Rule, California Bans All THCs In Hemp Products: Industry Asks, Where’s The Fire?

 
• By Malcolm Spicer

California authorities say predominance of retailers licensed to sell hemp are compliant with ban published effective on 3 October through emergency regulation. But hemp industry’s contesting the regulation in state court, arguing state authorities inappropriately used emergency action to change state law on hemp products legislature passed in 2021.

More from Policy & Regulation

Fragrance Industry Unification Hedges Against Tariff Impact – Experts

 
• By Eileen Francis

Fragrance companies and suppliers can draft contracts that ensure the cost burden of tariffs is shared, says attorney David Morrell of law firm Jones Day, during a recent panel discussion, ‘Tariffs in Motion: Insight for the Fragrance Industry.”

US Fragrance Firms Should Identify Domestic, Non-Tariff Sources Now – Fragrance House CEO

Firms in the US facing tariff costs should identify US-based, non-tariff sources and lobby local government officials and DC when foreign-sourced ingredients cannot be substituted in the US.

Cosmetics Consortium Shares Studies With FDA To Build Confidence In Animal Testing Alternatives

 
• By Lauren Nardella

By guiding regulators through case studies and mock dossier examples of how to utilize new approach methodologies, the International Collaboration on Cosmetics Safety hopes to counter hesitations in replacing animal tests.